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SHIPing news: A new way
to keep your weight down
Almost always, obesity is an obligate prerequisite for the development of type 2 diabetes mellitus. Loss of a well-known
lipid phosphatase appears to prevent insulin-resistant diabetes in mice by removal of a positive regulator of adiposity.In recent years, a substantial amount of s
attention has been directed toward un- p
tderstanding type 2 diabetes mellitus
(T2DM), both because of the disease’s t
rprofound impact on health care as well
as the intrinsically fascinating problem (
of how an efficient homeostatic mecha-
nism can be so considerably disrupted p
pby lifestyle changes. T2DM, formerly
known as adult-onset diabetes, is the e
omost common cause of hyperglycemia,
which is believed to result when increas- p
ting resistance to the actions of the hor-
mone insulin is accompanied by the fail- t
sure of the pancreatic β cell to keep pace
with the augmented needs for insulin p
tsecretion. Thus, a reasonable strategy to
alleviate the symptoms of T2DM would 1
nbe to enhance insulin’s action in classi-
cal target tissues such as muscle and a
ofat, and this is precisely the mechanism
used by the commonly prescribed thia- i
Szolidinedione class of drugs. However,
this action of thiazolidinediones was dis- (
acovered by chance, and current efforts
to develop novel therapeutics are t
eguided by more rational approaches.
Since it is generally believed that it is k
reasier to develop an inhibitor drug than
an activator one, a logical focus is path- a
rways that antagonize or terminate insu-
lin signaling. As shown in Figure 1, t
iphosphorylation of both proteins and
phospholipids is essential to insulin sig- (
fnaling, making the prospect of inhibiting
the enzymes that remove the critical i
ophosphates an attractive strategy for
drug development. In the current issue f
cof Nature Medicine, Sleeman et al. de-90cribe mice deficient in the lipid phos- t
thatase SH2 domain containing inosi-
ol 5-phosphatase 2 (SHIP2), identifying w
phis protein as an important negative
egulator of insulin action and adiposity o
tSleeman et al., 2005).
The best-studied example of im- t
broved hormone action by reduction in
hosphatase activity is provided by the t
lnhanced insulin sensitivity phenotype
f mice deficient for protein tyrosine e
whosphatase 1B (PT1B), the enzyme
hat dephosphorylates the insulin recep- s
lor (Elchebly et al., 1999). Likewise, tis-
ues lacking the 3# phosphoinositide p
mhosphatase, Pten (phosphatase and
ensin homolog deleted n chromosome s
t0), show improved insulin responsive-
ess (Komazawa et al., 2004; Stiles et e
pl., 2004; Wijesekara et al., 2005). An-
ther enzyme that degrades phospho- i
snositol 3,4,5 trisphosphate (PIP3) is
HIP2, which removes the 5# phosphate 2
dFigure 1). Sleeman et al. revisit the met-
bolic consequences of loss of SHIP2 in S
rhe mouse (Sleeman et al., 2005). An
arlier publication reported that SHIP2 a
cnockout mice displayed marked insulin
esponsiveness and death at an early t
ige due to hypoglycemia, though this
esult has been tempered by the au- t
ghors’ recent discovery that a neighbor-
ng gene was also inadvertently deleted m
uClement et al., 2001). Sleeman et al.
ind a much milder phenotype in which s
encreased insulin sensitivity is obvious
nly when mice are placed on a high- a
aat diet, a manipulation that increases fat
ell mass and promotes insulin resis- lance. More importantly, SHIP2 appears
o play a critical role in the control of
eight gain, and it is only through the
revention of obesity that the absence
f SHIP2 enhances the metabolic ac-
ions of insulin. This important distinc-
ion emphasizes the close relationship
etween body size and composition on
he one hand and the efficiency of insu-
in action on the other. In fact, even in
xperimental model systems, discerning
hether alterations in insulin respon-
iveness are direct or a consequence of
eanness is often a challenge. For exam-
le, two recent publications describing
ouse knockout experiments empha-
ize the importance of the genes studied
o optimal insulin signaling but do not
stablish definitively whether the gene
roducts normally antagonize peripheral
nsulin signaling or expansion of adipose
tores (Hirosumi et al., 2002; Um et al.,
004). Sleeman et al. address this issue
irectly and favor the idea that, in the
HIP2-deficient mice, improved insulin
esponsiveness results from reduced
diposity. Nonetheless, due to efficient
ompensatory mechanisms, it is some-
imes difficult in the mouse to assess
nsulin responsiveness, and many scien-
ists now regard the euglycemic hyper-
lycemic clamp as the most reliable
easure. Glucose levels are notoriously
nreliable, and though Sleeman et al.
ee no statistically significant differ-
nces in serum insulin when the animals
re on a chow diet, the absolute values
re 2-fold different. A decrease in circu-
ating insulin is a reasonable indicationCELL METABOLISM : FEBRUARY 2005
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rFigure 1. Cartoon depicting PI3 kinase signaling pathways in brain and peripheral tissues
A very abbreviated version of the signaling pathway involving SHIP2 is shown. The upper panel represents
peripheral tissues, whereas the lower panel refers to specialized cells of the hypothalamus. In both cases, M
SHIP2 and Pten degrade PIP3 to PI3,4P2 and PI4,5P2, respectively, which negatively regulate PI 3# kinase D
signaling and reduce Akt activity. Thus, in the periphery, blockade of SHIP2 would increase the activity of this
pathway and augment insulin’s ability to suppress hepatic glucose output or increase glucose uptake into
muscle. In hypothalamus, it has been suggested that there is a PI 3# kinase-dependent pathway that signals U
satiety in response to leptin and possibly insulin. Loss of SHIP2 in these cells would sensitize these pathways 4
and may explain the resistance to obesity in the SHIP2−/− mice.
Pof increased insulin responsiveness, t
suggesting that SHIP2-null mice might P
have improved insulin action even on a e
chow diet. In fact, activation of the PIP3- t
dependent protein kinase Akt/PKB in t
chow-fed SHIP2−/− mice is significantly s
more efficient under the same condi- p
tions. Even it were possible to detect en- e
hanced insulin sensitivity in these ani- F
mals, this would not prove a direct effect a
of SHIP2 on peripheral metabolism, as t
the chow-fed mice also show a reduction a
in fat pad size (Sleeman et al., 2005). s
An exciting and unsuspected issue
raised by these data is the mechanism e
by which loss of SHIP2 protects against p
obesity. On a high-fat diet, SHIP2−/− o
mice demonstrate an increased meta- n
bolic rate, suggesting but certainly not P
proving a central site of action. There is P
accumulating evidence that the protec- cCELL METABOLISM : FEBRUARY 2005S
ion from obesity afforded by loss of
BTP1B is due, at least in part, to neural
Rxpression of the phosphatase, and
Chere is substantial support for the idea
Bhat PIP3 is an important intermediary
Jignaling molecule in the hypothalamic
t
athway controlling satiety and energy
Expenditure (Barsh and Schwartz, 2002;
ligure 1). “Total body” knockouts often
C
re associated with ambiguity regarding (
he primary responsible organ, but brain-
Gnd muscle-specific SHIP2 ablation
D
hould provide very intriguing results. b
Another point to be taken from these 2
xperiments is the physiological roles
H
layed by different pathways for turn- C
ver of inositol phosphoinositides. As t
oted above and shown in the figure,
Kten removes the 3# phosphate from
n
IP3, producing PI4,5P2, whereas SHIP2 o
Monverts PIP to PI3,4P , itself an impor-3 2ant signaling lipid. For example, PIP3
nd PI3,4P2 each bind to Akt/PKB, the
ost important target downstream of
hosphoinositide 3# kinase, with ap-
roximately equal affinity. There is no
oubt that the consequences of loss of
ten are much more dramatic than that
f SHIP2, but it is unlikely that the roles
f the two phosphatases differ only by
egree or tissue distribution. Pten is
sually associated with the suppression
f growth, but careful experiments also
ndicate a role in metabolism (Koma-
awa et al., 2004; Stiles et al., 2004;
ijesekara et al., 2005). Unfortunately,
he abnormalities in the brain-specific
ten knockouts are so severe that it is
mpossible to evaluate the contribution
f Pten to control of appetite or energy
xpenditure (Groszer et al., 2001). As is
enerally the case, future resolution of
hese issues will be through a combina-
ion of physiological and biochemical
xperiments. For the time being, SHIP2
epresents an intriguing drug target as
ell as a tantalizing link between the
egulation of obesity and insulin action.
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